UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported):      November 19, 2003
                                                      --------------------------


                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)


       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)





<PAGE>



Item 5.  Other Events.

     On December 2,  2003,  Provectus  Pharmaceuticals,  Inc.  (the  "Company")
announced  that it has completed a short-term  unsecured  debt  financing in the
aggregate gross amount of $500,000 (the  "Offering").  On November 19, 2003, the
Company  issued in a  private  placement  to  "accredited  investors"  under the
Securities  Act of 1933,  as amended,  (i) $500,000 in the  aggregate  principal
amount of its 8% unsecured convertible debentures;  (ii) warrants to purchase up
to 500,000  shares of the Company's  common stock,  $.001 par value (the "Common
Stock") at an exercise price of $1.00 per share;  and (iii) warrants to purchase
up to 100,000 shares of the Company's Common Stock at an exercise price of $1.25
per  share.  The  Company  will use the  proceeds  of the  Offering  to  provide
short-term working capital.

     The Company issued a press release which is attached hereto as Exhibit 99.1
and incorporate herein by reference.


Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.


(c)  Exhibits.

     Exhibits required by Item 601 of Regulation S-B are incorporated  herein by
reference and are listed on the attached Exhibit Index, which begins on page X-1
of this Current Report on Form 8-K.





<PAGE>




                                   Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                      Provectus Pharmaceuticals, Inc.


Dated:   December 2, 2003            By:/s/ H. Craig Dees
                                      ------------------------------------------
                                      H. Craig Dees
                                      Chief Executive Officer

<PAGE>


                                  Exhibit Index

 Exhibit No.                      Description
--------------                    -----------

99.1          Press Release of Provectus Pharmaceuticals, Inc.
[{"type": "8-K", "sequence": "1", "filename": "prov8k111903.txt", "description": "CURRENT REPORT ON FORM 8-K", "secsgml_size_bytes": 3614}]
{"company-data": {"conformed-name": "PROVECTUS PHARMACEUTICALS INC", "cik": "0000315545", "assigned-sic": "2834", "irs-number": "900031917", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09410", "film-number": "031032494"}, "business-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931", "phone": "865-769-4011"}, "mail-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931"}, "former-company": [{"former-conformed-name": "ZAMAGE DIGITAL IMAGING INC", "date-changed": "20011126"}, {"former-conformed-name": "SPM GROUP INC", "date-changed": "19920703"}]}
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):      November 19, 2003
                                                      --------------------------

                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)

       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)
Item 5.  Other Events.

     On December 2,  2003,  Provectus  Pharmaceuticals,  Inc.  (the  "Company")
announced  that it has completed a short-term  unsecured  debt  financing in the
aggregate gross amount of $500,000 (the  "Offering").  On November 19, 2003, the
Company  issued in a  private  placement  to  "accredited  investors"  under the
Securities  Act of 1933,  as amended,  (i) $500,000 in the  aggregate  principal
amount of its 8% unsecured convertible debentures;  (ii) warrants to purchase up
to 500,000  shares of the Company's  common stock,  $.001 par value (the "Common
Stock") at an exercise price of $1.00 per share;  and (iii) warrants to purchase
up to 100,000 shares of the Company's Common Stock at an exercise price of $1.25
per  share.  The  Company  will use the  proceeds  of the  Offering  to  provide
short-term working capital.

     The Company issued a press release which is attached hereto as Exhibit 99.1
and incorporate herein by reference.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(c)  Exhibits.

     Exhibits required by Item 601 of Regulation S-B are incorporated  herein by
reference and are listed on the attached Exhibit Index, which begins on page X-1
of this Current Report on Form 8-K.
Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      Provectus Pharmaceuticals, Inc.

Dated:   December 2, 2003            By:/s/ H. Craig Dees
                                      ------------------------------------------
                                      H. Craig Dees
                                      Chief Executive Officer
Exhibit Index

 Exhibit No.                      Description
--------------                    -----------

99.1          Press Release of Provectus Pharmaceuticals, Inc.